From Strategy.
To Delivery.
We got you.
Strategy
01
Pipeline Strategy
Future market access requirements and key pricing levers — understood years before launch — often make the difference between truly successful P&R and making the best of a tough situation. Our team has navigated pipeline access optimization under uncertainty across therapeutic areas. We develop the right insights with you — competitive landscape, evidence gaps, commercial sensitivities. So your organization makes the decisions that pay off years later.
02
Commercial Potential
Commercial potential is about getting it right. Not about miracles falling from the sky — and not about the longest list of potential challenges. Our team has worked with clients for years after a valuation, all the way to launch. That's the expertise we bring from the very start: realistic pricing corridors, defensible patient numbers, scenarios that hold up under scrutiny. And the expectation we are happy to be measured on, every time.
03
Access Landscape
Market access is about navigating the system. Understanding Disease, patient pathways, key stakeholders, HTA and reimbursement pathways. They all matter — and they all interact. We work with you to map the landscape and develop a clear path to optimized P&R and patient access. So your innovation reaches the right patients at the right time.
04
Launch Readiness
Launching innovative Life Science products is complex. Some tasks are big. Others smaller and formal. Some are key — but need to be identified first. Our team puts years of launch experience to work in product-tailored roadmaps — every market access activity identified, cross-functionally aligned, sequenced against regulatory and pricing milestones. Risks surfaced early, while they can still be solved. So what really matters happens on time, for a successful launch.
05
Value Story
Let us be honest: We are evidence nerds. And while we are not alone with that, we know what it takes to transform a data package into a value story that sticks. We understand each stakeholder's perspective — payers, prescribers, patient associations, internal decision-makers. And develop a narrative backed by data, but one that speaks for itself. And resonates where it needs to.
06
Payer Research
Everyone does payer research. We know. Why are we different? Because while we have the network for large-scale panels, the real value lies in understanding which insights are actually sought — and who can really deliver them. Our team channels system expertise and network access into an engagement strategy tailored to the real knowledge gap. The right format, the right mix of national and regional voices. Insights that actually move decisions.
Real World Evidence
01
Claims Data
From epidemiology and target population size to patient pathways and burden of disease. Our experts have designed and delivered a wide range of tailor-made claims data studies. Large samples or the German Health Data Lab — whichever generates the insights you need.
02
Indication
registries
For value demonstration, patient-level real-world data bridges the gap from pivotal studies to market access needs. Our team has worked with many academic and industry-backed registries across indications. We know what it takes — from feasibility and study design to delivery and publication. From idea to impact.
03
Chart Reviews
Sometimes, the evidence that makes the difference goes beyond available data sources. Our team helps you identify eligible sites, develop the study concept, and align all relevant stakeholders and vendors. Fit-for-purpose evidence from patient chart data — when standard sources fall short.
04
G-BA mandated NIS
Sometimes, the evidence that makes the difference goes beyond available data sources. Our team helps you identify eligible sites, develop the study concept, and align all relevant stakeholders and vendors. Fit-for-purpose evidence from patient chart data — when standard sources fall short.
05
Indirect treatment comparisons
Indirect treatment comparisons fit for JCA and AMNOG must meet rigid methodological requirements — while still generating results that matter to caregivers and patients. Our team has solved this challenge many times — and stays close, every step of the way.
06
Hospital Data
For innovative pharmaceuticals, hospitals are a more frequented therapy setting than ever. Understanding case numbers, patient demographics, and associated procedures becomes crucial. So does uncovering the reimbursement and cost structures of relevant DRGs. Our team does both.
AMNOG & EU HTA
01
PICO Scoping
Getting the PICO right is at the core of successful HTA - on the national level and for products subject to HTAR. Our experts have led PICO identification, validation, and prioritization on European projects and national deep dives. Different methods, different angles. Let us cut through the complexity together.
02
HTA trial optimization
Unlocking the full value potential of innovative products requires translating HTA insights into global development programs. Our team supports every step — from insight generation to protocol changes, from risk mitigation to cross-functional alignment.
03
Joint scientific consultations (JSC)
Slots are limited — but JSCs offer unparalleled EU HTA alignment, with stakeholders and for internal awareness. Application strategy, briefing book, scientific positioning, meeting preparation. Our team brings the experience — combined with yours, we optimize your JCA positioning long before the formal procedure starts.
04
National HTA advice
Pricing and reimbursement remain national decisions. Germany continues to offer national HTA advice — for early trial planning, dossier PICO, and methodological questions. Our team has completed many advice projects across therapeutic areas. Your science and product knowledge combined with our process expertise — that's how we make the most of our joint perspectives.
05
JCA & AMNOG strategy
Holistic HTA strategy goes beyond PICO and evidence presentation. It's about therapeutic positioning, pricing strategy, and evidence packages. It's about internal alignment and clear expectation management. Bringing all of these together — at the right time, in the right sequence. So you can invest your resources where it impacts most.
06
AMNOG & delta dossiers
Full-service AMNOG and delta dossiers from a single source — added benefit, epidemiology, biostatistics, pricing. Our team aligns every element into a coherent, defensible submission that holds up where it counts. Because the dossier is where the AMNOG case is made. And where surprises are most expensive.
07
Statistical analysis planning
Tailor-made post-hoc analyses to demonstrate the true value of innovation. Our team works hand-in-hand with your statisticians to design analyses fit for AMNOG — methodologically rigorous, aligned with the value story. Pre-specified where it counts, exploratory where it adds. So your evidence speaks where it matters most.
08
Written statement
All hands on deck. When surprises arrive in the dossier assessment, our team focuses on both strategy and delivery — addressing G-BA's questions in ways that strengthen rather than dilute the case. Reframe where it helps. Concede where it's wise. Hold the line where it counts. From rapid analysis to final response, we are with you when it matters.
09
Oral hearing
The most important hour. Our team prepares you with realistic scenarios and team training — or joins you at the table. From rehearsal to the finest hour, ready for the questions that decide outcomes. Years of oral hearings behind us mean we know what to expect — and how to shape what neets to stick.
Pricing
01
Early Price
Corridors
Pricing is art. Predicting a realistic price is science — blended with experience. Major commercial and R&D decisions depend on getting the corridor right years before launch, and continuously after. Despite natural uncertainty and variance in future scenarios. Our team blends AI-enabled data analysis and predictive modelling with pricing experience and political awareness. The goal: predict and validate price corridors for pipeline products. And narrow them with you as launch approaches.
02
Launch Price
Strategy
"In Germany, you submit tens of thousands of pages of data — and in the end, you negotiate a 20% rebate." We all know that's not quite true. But setting the launch price is critical. From international price referencing to mandatory rebates, from competitive aspects to negotiation strategy. Choose the launch price with the end in mind. Our team helps you validate, challenge, and optimize — backed by the numbers and the strategic goal.
03
Price Negotiation Simulation
There will always be surprises along the journey of AMNOG price negotiations. Good preparation reduces them dramatically, though. Our team systematically identifies potential negotiation topics, develops a robust strategy with you, and puts you through realistic simulations. To know what's ahead — and to feel what works and what may not.
04
AMNOG price negotiations
We don't stop at preparations and simulations. When it matters, our team is with you — full group attendance or 8-eye discussions. We leverage years of negotiation experience to find a robust path through the meetings. And support you holistically through the entire AMNOG process. From dossier strategy to written response, from oral hearing to re-negotiations. For us, negotiation support means all of it.
05
Payer Research
Everyone does payer research. We know. Why are we different? Because while we have the network for large-scale panels, the real value lies in understanding which insights are actually sought — and who can really deliver them. Our team channels system expertise and network access into an engagement strategy tailored to the real knowledge gap. The right format, the right mix of national and regional voices. Insights that actually move decisions.
06
Hospital Data
For innovative pharmaceuticals, hospitals are a more frequented therapy setting than ever. Therefore, understanding case or patient numbers and demograpghics as well as associated procedures becomes curcial. We are also uncovering reimbursement and cost structures of relevant DRGs.
Patient Access
01
Reimbursement Pathways
Innovative pharmaceuticals need to find their place within an existing care setting. Patients need the prescription at the right place at the right time of their therapy. Physicians need a hurdle-free path — without worrying about bureaucracy, budgets, or resources. Don't think outpatient or inpatient. Think cross-sector. Let our team help you map and uncover your network.
02
Volume Restrictions
Speaking of physician budgets: regionally managed, semi-transparent, and just tedious to work with. Our team guides you through the mechanisms — and steers your attention (and your field force's) to where it matters most. Tools, materials, KV-specific signals. Let us find out together what your physicians need in your indication.
03
Hospital Reimbursement
Outpatient reimbursement: a physician writes a prescription. Done. Inpatient reimbursement: not so straightforward. Is your drug already financed in the DRG system? Is an additional reimbursement rate required? Have you ensured your hospitals qualify? Creating reimbursement in hospitals where there was none before — that's something our team can help you with.
04
Stakeholder Management
Learning from a product's key stakeholders — and channeling those insights into market access strategy — can be invaluable. To benefit, you need to understand who they are, what drives them, and what they recommend. Our team helps you map the landscape, prioritize who to engage and how, and design touchpoints that fit your timeline. From KOLs to patient associations to system stakeholders — engagement that informs strategy, not just decoration.